
    
      This is a phase II study that seeks to treat patients ages 18-59 who have acute myeloid
      leukemia but have never been treated before. It will use venetoclax and azacitidine, and
      patients can receive up to four cycles of this medication. Depending on the level of
      recovery, patients will either be forced to come off study or have the option to continue the
      medication, receive maintenance therapy, or pursue an allogeneic stem cell transplant.
    
  